Nian Liu

Dr. Nian Liu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Heart Rhythm
Verified
Journal Article
Closed access
LJLe Jiang
Le Jiang
LLLinling Li
Linling Li
YRYanfei Ruan
Yanfei Ruan
SZSong Zuo
Song Zuo
XWXiaoyan Wu
Xiaoyan Wu
CMChangsheng Ma
Changsheng Ma

1 February 2020 in Redox Biology
Verified
Journal Article
Open access
XYXinyu Yang
Xinyu Yang
NANa An
Na An
CZChangming Zhong
Changming Zhong
MGManke Guan
Manke Guan
YJYuchen Jiang
Yuchen Jiang
YXYanwei Xing
Yanwei Xing
Atrial fibrillation (AF) occurs in up to 11% of cancer patients treated with ibrutinib. The pathophysiology of ibrutinib promoted AF is complicated, as there are multiple interactions involved; the detailed molecular mechanisms underlying this are still unclear. Here, we aimed to determine the electrophysiological and molecular mechanisms of burst-pacing-induced AF in ibrutinib-treated mice. The results indicated differentially expressed proteins in ibrutinib-treated mice, identified through proteomic analysis, were found to play a role in oxidative stress-related pathways. Finally, treatment with an inhibitor of NADPH oxidase (NOX) prevented and reversed AF development in ibrutinib-treated mice. It was showed that the related protein expression of reactive oxygen species (ROS) in the ibrutinib group was significantly increased, including NOX2, NOX4, p22-phox, XO and TGF-β protein expression. It was interesting that ibrutinib group also significantly increased the expression of ox-CaMKII, p-CaMKII (Thr-286) and p-RyR2 (Ser2814), causing enhanced abnormal sarcoplasmic reticulum (SR) Ca2+ release and mitochondrial structures, as well as atrial fibrosis and atrial hypertrophy in ibrutinib-treated mice, and apocynin reduced the expression of these proteins. Ibrutinib-treated mice were also more likely to develop AF, and AF occurred over longer periods. In conclusion, our study has established a pathophysiological role for ROS signaling in atrial cardiomyocytes, and it may be that ox-CaMKII and p-CaMKII (Thr-286) are activated by ROS to increase AF susceptibility following ibrutinib treatment. We have also identified the inhibition of NOX as a potential novel AF therapy approach.

4 August 2020 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
XPXiaodong Peng
Xiaodong Peng
LLLinling Li
Linling Li
MZMengxia Zhang
Mengxia Zhang
QZQianqian Zhao
Qianqian Zhao
KWKui Wu
Kui Wu
NLNian Liu
Nian Liu
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering agents that significantly improve the prognosis of patients with type 2 diabetes (T2D) and heart failure. SGLT2i has recently been implicated in the treatment of atrial fibrillation (AF) with clinical data demonstrating that these agents decrease the incidence of AF events in patients with T2D. Fundamental findings have suggested that SGLT2i may alleviate atrial electrical and structural remodeling. The underlying mechanisms of SGLT2i are likely associated with balancing the sodium and calcium handling disorders and mitigating the mitochondrial dysfunction in atrial myocytes. This review illustrates the advances in understanding the underlying mechanisms of SGLT2i as an evolving treatment modality for AF.

24 May 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YLYiwei Lai
Yiwei Lai
XLXiaoxia Liu
Xiaoxia Liu
CSCaihua Sang
Caihua Sang
DLDeyong Long
Deyong Long
MLMengmeng Li
Mengmeng Li
CMChangsheng Ma
Changsheng Ma

13 December 2014 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
JNJun-Gang Nie
Jun-Gang Nie
JDJianzeng Dong
Jianzeng Dong
MSMohamed Salim
Mohamed Salim
SLSong-Nan Li
Song-Nan Li
XWXiao-Yan Wu
Xiao-Yan Wu
CMChangsheng Ma
Changsheng Ma

11 April 2019 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
CLChang Liu
Chang Liu
XDXin Du
Xin Du
CJChao Jiang
Chao Jiang
LHLiu He
Liu He
SCSan-Shuai Chang
San-Shuai Chang
CMChangsheng Ma
Changsheng Ma
BACKGROUND:Oral anticoagulants (OACs) such as warfarin and non-VKA oral anticoagulants (NOACs) have been recommended for patients with atrial fibrillation (AF) who are at risk for stroke. Whether NOACs have a higher persistence than warfarin is still...